Fibrogen
Presence
Fibrogen is one of the...
Fibrogen is a company listed under the stock ticker FGEN (US).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Fibrogen
- Thane Wettig, Chief Executive Officer and Director
- Jeffrey Edwards, Director
- James Schoeneck, Chairman of the Board
Popular executive movements at Fibrogen
- Deyaa Adib has joined the company as Senior Vice President and Chief Medical Officer (posted on March 12 2024).
- Thane Wettig, who was Interim Chief Executive Officer, is promoted to Chief Executive Officer and Director (posted on October 6 2023).
- Mark Eisner, Executive Vice President and Chief Medical Officer, has left the company (posted on September 15 2023).
Create your alert
to follow the executive moves at Fibrogen.
Biotechnology
Fibrogen has 2,285 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Fibrogen
- FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined | FibroGen, Inc.
- FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer | FibroGen, Inc.
- FibroGen to Present at Upcoming Investor Conferences | FibroGen, Inc.
- FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy | FibroGen, Inc.
- FibroGen Reports Second Quarter 2020 Financial Results | FibroGen, Inc.
- FibroGen Announces New Appointments to its Board of Directors | FibroGen, Inc.
- FibroGen to Report Second Quarter 2020 Financial Results | FibroGen, Inc.
- FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19 | FibroGen, Inc.
- FibroGen Appoints Thane Wettig as Chief Commercial Officer | FibroGen, Inc.
- FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress | FibroGen, Inc.
- View more press releases Close
Social media about Fibrogen
- Fibrogen on Wikipedia, Google News & Yahoo Finance
- Fibrogen on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Thane Wettig 
